Scott A. Rollins

9.5k total citations · 3 hit papers
63 papers, 7.2k citations indexed

About

Scott A. Rollins is a scholar working on Immunology, Surgery and Hematology. According to data from OpenAlex, Scott A. Rollins has authored 63 papers receiving a total of 7.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Immunology, 22 papers in Surgery and 19 papers in Hematology. Recurrent topics in Scott A. Rollins's work include Complement system in diseases (28 papers), Xenotransplantation and immune response (12 papers) and Mechanical Circulatory Support Devices (10 papers). Scott A. Rollins is often cited by papers focused on Complement system in diseases (28 papers), Xenotransplantation and immune response (12 papers) and Mechanical Circulatory Support Devices (10 papers). Scott A. Rollins collaborates with scholars based in United States, Switzerland and United Kingdom. Scott A. Rollins's co-authors include Russell P. Rother, PJ Sims, Christopher F. Mojcik, Louis A. Matis, Robert A. Brodsky, Leonard Bell, Stephen P. Squinto, Peter Hillmen, Gregory L. Stahl and Azin Agah and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and JAMA.

In The Last Decade

Scott A. Rollins

62 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

2006 878 citations Peter Hillmen, Neal S. Young et al. New England Journal of Medicine profile →
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

2016 595 citations Kenneth I. Ataga, Abdullah Kutlar et al. New England Journal of Medicine profile →
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

2007 570 citations Russell P. Rother, Scott A. Rollins et al. Nature Biotechnology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott A. Rollins United States	38	4.1k	1.9k	1.5k	1.4k	1.3k	63	7.2k
Russell P. Rother United States	34	4.7k 1.1×	2.4k 1.2×	716 0.5×	2.0k 1.5×	2.0k 1.5×	72	7.9k
Yoshihiro Fujimura Japan	47	4.1k 1.0×	4.4k 2.3×	693 0.5×	1.8k 1.3×	1.5k 1.2×	249	8.1k
Laure‐Hélène Noël France	51	2.3k 0.6×	1.1k 0.6×	978 0.6×	3.8k 2.8×	1.0k 0.8×	179	8.1k
X. Long Zheng United States	43	3.8k 0.9×	3.2k 1.7×	380 0.3×	1.4k 1.0×	1.5k 1.2×	181	5.9k
David Kavanagh United Kingdom	47	5.8k 1.4×	2.3k 1.2×	232 0.2×	3.3k 2.4×	902 0.7×	138	7.9k
Falk Hiepe Germany	54	7.2k 1.8×	1.0k 0.5×	461 0.3×	594 0.4×	794 0.6×	250	11.8k
Leendert A. Trouw Netherlands	55	4.7k 1.2×	1.2k 0.6×	363 0.2×	1.1k 0.8×	553 0.4×	218	9.8k
Élie Haddad Canada	46	3.2k 0.8×	1.9k 1.0×	474 0.3×	555 0.4×	615 0.5×	179	6.9k
Christopher F. Mojcik United States	21	2.2k 0.5×	906 0.5×	375 0.2×	991 0.7×	520 0.4×	35	3.6k
Philippe Lesavre France	38	3.0k 0.7×	1.1k 0.6×	295 0.2×	1.9k 1.4×	863 0.7×	107	6.5k

Countries citing papers authored by Scott A. Rollins

Since Specialization

Citations

This map shows the geographic impact of Scott A. Rollins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Rollins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Rollins more than expected).

Fields of papers citing papers by Scott A. Rollins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Rollins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Rollins. The network helps show where Scott A. Rollins may publish in the future.

Co-authorship network of co-authors of Scott A. Rollins

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Rollins. A scholar is included among the top collaborators of Scott A. Rollins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Rollins. Scott A. Rollins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donnelly, G, et al.. (2024). Prioritise safety, optimise success! Return to rugby postpartum. European Journal of Sport Science. 24(12). 1701–1718. 5 indexed citations

Ataga, Kenneth I., Abdullah Kutlar, Julie Kanter, et al.. (2016). Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. New England Journal of Medicine. 376(5). 429–439. 595 indexed citations breakdown →

Rother, Russell P., Scott A. Rollins, Christopher F. Mojcik, Robert A. Brodsky, & Leonard Bell. (2007). Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nature Biotechnology. 25(11). 1256–1264. 570 indexed citations breakdown →

Armstrong, Paul W., Kenneth W. Mahaffey, Wei-Ching Chang, et al.. (2006). Concerning the mechanism of pexelizumab's benefit in acute myocardial infarction. American Heart Journal. 151(4). 787–790. 15 indexed citations

Hillmen, Peter, Neal S. Young, Jörg Schubert, et al.. (2006). The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. New England Journal of Medicine. 355(12). 1233–1243. 878 indexed citations breakdown →

Théroux, Pierre, Paul W. Armstrong, Kenneth W. Mahaffey, et al.. (2005). Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. European Heart Journal. 26(19). 1964–1970. 94 indexed citations

Chen, John C., Scott A. Rollins, Stanton K. Shernan, et al.. (2005). Pharmacologic C5-Complement Suppression Reduces Blood Loss During On-Pump Cardiac Surgery. Journal of Cardiac Surgery. 20(1). 35–41. 6 indexed citations

Théroux, Pierre, Paul W. Armstrong, Kenneth W. Mahaffey, et al.. (2004). 833-5 Markers of inflammation predict mortality and are reduced by pexelizumab in patients with acute myocardial infarction: Insights from the complement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Journal of the American College of Cardiology. 43(5). A287–A287. 5 indexed citations

Verrier, Edward D., Stanton K. Shernan, Kenneth M. Taylor, et al.. (2004). Terminal Complement Blockade With Pexelizumab During Coronary Artery Bypass Graft Surgery Requiring Cardiopulmonary Bypass. JAMA. 291(19). 2319–2319. 138 indexed citations

10.

Collard, Charles D., Antti Väkevä, Azin Agah, et al.. (2000). Complement Activation after Oxidative Stress. American Journal Of Pathology. 156(5). 1549–1556. 284 indexed citations

11.

Wang, Hao, Scott A. Rollins, Zu‐Hua Gao, et al.. (1999). COMPLEMENT INHIBITION WITH AN ANTI-C5 MONOCLONAL ANTIBODY PREVENTS HYPERACUTE REJECTION IN A XENOGRAFT HEART TRANSPLANTATION MODEL1. Transplantation. 68(11). 1643–1651. 41 indexed citations

12.

Rinder, Christine S., Henry M. Rinder, Michael J. Smith, et al.. (1999). Selective blockade of membrane attack complex formation during simulated extracorporeal circulation inhibits platelet but not leukocyte activation. Journal of Thoracic and Cardiovascular Surgery. 118(3). 460–466. 39 indexed citations

13.

Rollins, Scott A., Carl Birks, E Setter, Stephen P. Squinto, & Russell P. Rother. (1996). Retroviral Vector Producer Cell Killing in Human Serum Is Mediated by Natural Antibody and Complement: Strategies for Evading the Humoral Immune Response. Human Gene Therapy. 7(5). 619–626. 24 indexed citations

14.

Fodor, William L., Scott A. Rollins, Willis V. Burton, et al.. (1995). Primate terminal complement inhibitor homologues of human CD59. Immunogenetics. 41(1). 51–51. 13 indexed citations

15.

Rinder, Christine S., Henry M. Rinder, Brian R. Smith, et al.. (1995). Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.. Journal of Clinical Investigation. 96(3). 1564–1572. 181 indexed citations

16.

Evans, Mark J., Scott A. Rollins, Dennis W. Wolff, et al.. (1995). In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5. Molecular Immunology. 32(16). 1183–1195. 38 indexed citations

17.

Sandrin, Mauro S., William L. Fodor, Narin Osman, et al.. (1995). Enzymatic remodelling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Medicine. 1(12). 1261–1267. 249 indexed citations

18.

Rollins, Scott A., Scott P. Kennedy, A Chodera, et al.. (1994). EVIDENCE THAT ACTIVATION OF HUMAN T CELLS BY PORCINE ENDOTHELIUM INVOLVES DIRECT RECOGNITION OF PORCINE SLA AND COSTIMULATION BY PORCINE LIGANDS FOR LFA-1 AND CD2. Transplantation. 57(12). 1709–1716. 83 indexed citations

19.

Rollins, Scott A., Mark J. Evans, Krista Johnson, et al.. (1994). Molecular and Functional Analysis of Porcine E-Selectin Reveals a Potential Role in Xenograft Rejection. Biochemical and Biophysical Research Communications. 204(2). 763–771. 23 indexed citations

20.

Ninomiya, Hirokazu, et al.. (1992). Contribution of the N-linked carbohydrate of erythrocyte antigen CD59 to its complement-inhibitory activity.. Journal of Biological Chemistry. 267(12). 8404–8410. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact